Adimmune Corporation (TPE:4142)
Taiwan
· Delayed Price · Currency is TWD 17.55
+0.05 (0.29%)
Jun 6, 2025, 1:30 PM CST
Adimmune Revenue
Adimmune had revenue of 72.10M TWD in the quarter ending March 31, 2025, with 64.33% growth. This brings the company's revenue in the last twelve months to 1.59B, down -4.46% year-over-year. In the year 2024, Adimmune had annual revenue of 1.56B, down -12.78%.
Revenue (ttm)
1.59B
Revenue Growth
-4.46%
P/S Ratio
4.67
Revenue / Employee
2.81M
Employees
564
Market Cap
7.40B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.56B | -228.11M | -12.78% |
| Dec 31, 2023 | 1.79B | -466.53M | -20.72% |
| Dec 31, 2022 | 2.25B | 457.85M | 25.52% |
| Dec 31, 2021 | 1.79B | -75.37M | -4.03% |
| Dec 31, 2020 | 1.87B | 569.46M | 43.81% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| PharmaEssentia | 11.34B |
| Caliway Biopharmaceuticals | 40.47M |
| Bora Pharmaceuticals Co., LTD. | 20.87B |
| Lotus Pharmaceutical | 19.12B |
| Polaris Group | 87.67M |
| Lumosa Therapeutics | 43.59M |
| Center Laboratories | 1.63B |
| Oneness Biotech | 117.33M |